An Oral Secretagogue, Not a SARM
MK-677 (Ibutamoren) is frequently mischaracterized in fitness circles as a SARM (Selective Androgen Receptor Modulator). This is pathologically incorrect. MK-677 is an oral, non-peptide growth hormone secretagogue. It binds exclusively to the ghrelin receptor (GHS-R1a) in the pituitary and hypothalamus, completely bypassing androgen receptors.
Unlike peptide secretagogues (such as Ipamorelin or CJC-1295) which require subcutaneous injection, MK-677 is an active spiroindoline sulfonamide that survives first-pass hepatic metabolism. A single oral dose stimulates a prolonged, 24-hour elevation of both Growth Hormone (GH) and Insulin-Like Growth Factor 1 (IGF-1).
Clinical Efficacy vs. Metabolic Risk
The clinical data on MK-677 is substantial. In placebo-controlled trials (e.g., Svensson et al., 1998), an oral dose of 25mg/day successfully elevated IGF-1 by 60% and increased fat-free mass over a 12-month period in healthy older adults.
However, this sustained, unnatural 24-hour elevation comes with a severe metabolic penalty: insulin resistance. Because MK-677 mimics ghrelin—the hormone that signals starvation—it aggressively stimulates appetite and elevates fasting blood glucose. Chronic administration frequently pushes users into prediabetic HbA1c ranges if not actively monitored and mitigated.
Dosing Tiers: Diminishing Returns
Clinical consensus in optimization circles strongly cautions against the original 25mg trial doses, favoring a "minimum effective dose" approach to mitigate glycemic disruption:
• 10 mg/day (The Optimization Dose): Provides approximately 80% of the maximum IGF-1 elevation possible with MK-677, while keeping fasting glucose elevation minimal. This is the preferred dose for longevity and sleep architecture enhancement.
• 15 mg/day (The Threshold Dose): The maximum dose recommended before insulin resistance becomes difficult to manage without exogenous intervention (e.g., Berberine, Metformin).
• 25 mg/day (The Clinical Trial Dose): Maximizes IGF-1 but reliably induces severe appetite stimulation, water retention (edema), and fasting glucose elevation. Highly discouraged for long-term use.
Optimal Timing and Administration
Due to its profound somnogenic (sleep-inducing) properties and intense appetite stimulation, MK-677 should be administered once daily, 30-60 minutes before bed. Nocturnal dosing aligns the drug's initial pulse with the body's natural Stage 4 deep sleep cycle and allows the user to sleep through the most aggressive peak of ghrelin-induced hunger.